LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Suletud

SektorTervishoid

215.17 -1.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

213.19

Max

216.59

Põhinäitajad
By Trading Economics
Sissetulek	-22M -61M
Müük	56M 214M
Kasumimarginaal	-28.549
Töötajad	1,017
EBITDA	-56M -53M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.78% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.7B 14B
Eelmine avamishind	216.43
Eelmine sulgemishind	215.17

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

157.66 / 167.29 Toetus ja vastupanu

Ascendis Pharma A-S ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. veebr 2026, 16:32 UTC

Tulu

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14. veebr 2026, 22:02 UTC

Tulu

Looking for Dividends? Consider Europe. -- Barrons.com

14. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:57 UTC

Tulu

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:20 UTC

Tulu

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. veebr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. veebr 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. veebr 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. veebr 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. veebr 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. veebr 2026, 19:51 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:29 UTC

Tulu

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. veebr 2026, 18:18 UTC

Omandamised, ülevõtmised, äriostud

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. veebr 2026, 17:52 UTC

Tulu

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. veebr 2026, 17:16 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. veebr 2026, 16:59 UTC

Tulu

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. veebr 2026, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. veebr 2026, 16:11 UTC

Tulu

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. veebr 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. veebr 2026, 15:54 UTC

Tulu

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. veebr 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. veebr 2026, 15:01 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. veebr 2026, 15:00 UTC

Tulu

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. veebr 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. veebr 2026, 14:44 UTC

Tulu

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. veebr 2026, 14:22 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Ascendis Pharma A-S ADR Prognoos

Hinnasiht

By TipRanks

31.78% tõus

12 kuu keskmine prognoos

Keskmine 287.42 USD 31.78%

Kõrge 342 USD

Madal 250 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Ascendis Pharma A-S ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Ascendis Pharma A-S ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

157.66 / 167.29Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.